Market Overview:
Cancer chemotherapy associated nausea and vomiting therapeutics aim at reducing nausea and vomiting caused during chemotherapy. Antiemetic drugs act on different receptor sites in the brain regions implicated in vomiting.
The global cancer chemotherapy associated nausea and vomiting therapeutics market is estimated to be valued at US$ 3,071.1 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising number of cancer patients undergoing chemotherapy is contributing to the growth of the market. According to WHO, cancer burden rose to 19.3 million cases and 10 million cancer deaths in 2020. Also, development of new antiemetic drugs with novel mechanisms of action and improved efficacy is driving the market growth. For instance, in 2021, Heron Therapeutics, Inc. got FDA approval for Zynrelef, the first dual-acting peripheral nerve block to reduce pain and prevent opioid-induced nausea and vomiting for 24 hours post surgery.
Segment Analysis
The global cancer chemotherapy associated nausea and vomiting therapeutics market can be segmented into treatment, route of administration, distribution channel, and geography. By treatment, the market can be segmented into serotonin receptor antagonists, neurokinin-1 receptor antagonists, and other therapies like dexamethasone. Among these, the neurokinin-1 receptor antagonists segment currently dominates the market due to its high efficacy and minimal side effects compared to other available therapies.
Key Takeaways
The Global Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Size is expected to witness high growth, exhibiting CAGR of 5.7% over the forecast period, due to increasing prevalence of cancer and growing requirement for effective anti-emetic therapies.
Regional analysis
North America currently dominates the global cancer chemotherapy associated nausea and vomiting therapeutics market due to presence of major players and rising healthcare expenditure. Asia Pacific is expected to be the fastest growing regional market over the forecast period due to increasing funding for cancer research and rapidly developing healthcare infrastructure in the region.
Key players
Key players operating in the cancer chemotherapy associated nausea and vomiting therapeutics market are Johnson & Johnson Services, Inc., Teleflex Incorporated, Cooper Surgical, Inc., Genicon, Medtronic, B. Braun SE, Applied Medical Resources Corporation, LaproSurge, Purple Surgical, CONMED, Hangzhou Boer Medical Instruments Co., Ltd., Duomed, Changzhou Cheayoo Medical Devices Co., Ltd., and Tianjin Zhichao Medical Technology Co., Ltd. Neurokinin-1 receptor antagonists segment currently dominates the market due to its high efficacy and minimal side effects compared to other available therapies.
For More Insights, Read: https://www.newsstatix.com/cancer-chemotherapy-associated-nausea-and-vomiting-therapeutics-market-size-share-and-growth-forecast-2023-2030/
Comments
0 comment